United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter

United Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Third-quarter revenue reached $833 million, including about $504 million from TYVASO. United Therapeutics recorded more than 1,000 referrals across its portfolio in October and expects its expanded sales force to support growth.
  • The FDA accepted the application for nebulized TYVASO to treat idiopathic pulmonary fibrosis, with a decision expected by April 26, 2027. The company is preparing launch supplies for at least 10,000 patients if approved.
  • Key pipeline milestones include a June 2027 FDA decision date for ralinepag and TETON trial readouts in progressive pulmonary fibrosis in the second half of 2027. The board also authorized an additional $2 billion in share repurchases.
  • Interested in United Therapeutics? Here are five stocks we like better.

United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory and clinical milestones at the UBS London Healthcare Conference.

The company reported third-quarter revenue of $833 million, including approximately $504 million from TYVASO, Chief Financial Officer James Edgemond said. He attributed the quarter’s growth partly to referrals and patient starts that began building in the preceding quarter.

United Therapeutics recorded more than 1,000 referrals across its commercial portfolio in October, its highest total for a single month, Edgemond said. He expects the impact of a sales force expansion undertaken around July and August to become more apparent in the fourth quarter and into 2027.

TYVASO Growth and Potential IPF Launch

Harry Silvers, senior manager of investor relations, said pulmonary hypertension associated with interstitial lung disease, or PH-ILD, remains underpenetrated and is the larger growth opportunity for the existing TYVASO business. Pulmonary arterial hypertension, or PAH, is also growing, though more modestly, he said.

Asked whether off-label use in idiopathic pulmonary fibrosis, or IPF, could be contributing to sales, Edgemond said it was possible but that the company does not market TYVASO for that use. He said United Therapeutics would have limited visibility into such prescribing because the drug is not specifically reimbursable for IPF.

Executives also discussed the company’s settlement with Liquidia involving YUTREPIA. Silvers said any changes to payer coverage following a label update removing PH-ILD would vary by insurer. Edgemond said provisions of the settlement should, over time, help direct new PH-ILD patients toward TYVASO.

The Food and Drug Administration has accepted United Therapeutics’ supplemental application for nebulized TYVASO in IPF, with a decision date of April 26, 2027, Edgemond said. The company is preparing enough nebulizers to support at least 10,000 IPF patients at launch, if the treatment is approved.

Edgemond said he anticipates rapid uptake based on results from the TETON-1 and TETON-2 trials, despite the difference between a nebulized treatment and an oral therapy. Silvers said it remains uncertain how discontinuation rates observed in a clinical trial will translate to real-world use.

Pipeline and Regulatory Updates

United Therapeutics expects to file its application for SMI in 2027 rather than at the end of 2026, Silvers said. Following a recent FDA meeting, the company determined it needed more time for chemistry, manufacturing and controls, and pharmacokinetic work. Silvers said the company does not expect to need additional patient outcomes data.

For ralinepag, an investigational once-daily oral prostacyclin for PAH, Edgemond said the FDA decision date is at the end of June 2027. He said the company is monitoring discussions between manufacturer Sinopharm and the FDA about agency findings while also exploring additional manufacturers. Edgemond said there remains a path to being ready by the decision date if matters proceed as planned.

The company also expects its TETON trials in progressive pulmonary fibrosis to be unblinded in the third and fourth quarters of 2027, Edgemond said.

Xenotransplantation and Capital Allocation

In xenotransplantation, Silvers said the company expects the sixth and final patient in an initial cohort to receive a transplant by year-end. Twelve weeks later, United Therapeutics plans to meet with the FDA to determine whether it can proceed to a second cohort of up to 44 additional patients intended to support a biologics license application. The cohort could potentially be smaller, he said.

Edgemond said United Therapeutics’ capital allocation priorities remain internal investment, followed by corporate or business development and then share repurchases. The board recently authorized another $2 billion in repurchases, he said, while the company also used capital to reduce a royalty payable to Pfizer associated with ralinepag.

About United Therapeutics (NASDAQ:UTHR)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in United Therapeutics Right Now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines